|
USA-NM-BETHESDA Azienda Directories
|
Azienda News:
- Considerations for open-label clinical trials: design, conduct, and . . .
Double-blind: often used to describe a fully blind trial, but the term double-blind is vague and, when used, should be clearly defined as to how blinding was conducted and who exactly was
- Double-Blind Study - StatPearls - NCBI Bookshelf
Single-, double-, and triple-blinding are commonly used blinding strategies in clinical research A single-blind study masks the subjects from knowing which study treatment, if any, they are receiving
- Impact of open-label versus blinded study design on patient-reported . . .
Aim: A systematic literature review of immuno-oncology trials was conducted to assess the potential impact of open-label vs double-blind trial design on patient-reported outcome (PRO) data Methods: A systematic search of indexed literature published from January 2009 to May 2019 was conducted using PubMed MEDLINE, Cochrane Library, and EMBASE
- Open-Label vs Blinded vs Double-Blind Studies | Clinical Trial Designs
Understand the differences between open-label, single-blind, and double-blind studies in clinical trials, their purposes, and why double-blind is the gold standard
- Considerations for open-label randomized clinical trials: Design . . .
In this article, we review how best to design, conduct, and analyze open-label trials to ensure the highest level of study integrity and the reliability of the study conclusions
- Open-Label Clinical Trials - How Are They Run and When Are They . . .
Double-blind, on the other hand, means that both parties (the patient and investigator) do not know which treatment a patient is receiving Blind trials are fully randomized, and controlled in the hope of reducing potential bias from either party
- Open-label placebo vs double-blind placebo for irritable bowel syndrome . . .
The study showed that participants receiving open-label placebo (OLP) reported greater improvement in IBS symptoms with meaningful clinical impact compared to a control group who did not receive placebo (i e ‘no-pill control’)
- Impact of double-blind vs. open study design on the observed treatment . . .
Different designs with respect to blinding of partici-pants and researchers have been used to assess the effi-cacy and safety of NOAs, namely double-blind (DB), open-label, and prospective, randomized, open, blinded endpoint evaluation (PROBE) designs [9,10]
- Impact of Open-Label Design on Patient-Reported Outcomes (PROs) Data in . . .
In this context, we conducted a SLR of IO trials across indications, to assess and quantify the potential impact of open-label vs double-blind designs on treatment effects of PROs
- Considerations for open-label clinical trials: design, conduct, and . . .
This poster reviews what can be done to improve a trial design, conduct, and analysis when fully blinding a trial is not considered possible
|
|